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REVIEW
Early lung cancer detection by low-dose CT screening: therapeutic implications
Marjolein A Heuvelmansa,b, Harry J M Groenc and Matthijs Oudkerka
aUniversity of Groningen, University Medical Center Groningen, Center for Medical Imaging – North East Netherlands, Groningen, The Netherlands;
bMedisch Spectrum Twente, Department of Pulmonology, Enschede, The Netherlands; cUniversity of Groningen, University Medical Center
Groningen, Department of Pulmonology, Groningen, The Netherlands
ABSTRACT
Introduction: Lung cancer screening by low-dose chest computed tomography is currently implemen-
ted in the U.S. After implementation of screening, a stage shift may be observed from around 15% stage
I non-small cell lung cancers (NSCLCs) in routine clinical practice to up to 70% in screening patients.
This indicates a move in treatment options from advanced to early lung cancers, especially in those with
small suspected intrapulmonary nodules.
Areas covered: We have reviewed the current status of lung cancer screening from the different
randomized controlled lung cancer screening studies and the clinical evidence so far for both surgical
and non-surgical treatment options for (screen-detected) stage I NSCLC. Furthermore, we provide a
step-wise approach for the treatment of stage I NSCLC.
Expert Commentary: Recommended treatment for stage I NSCLC remains (VATS) lobectomy in case of
a medically operable patient, VATS sublobar resection for subcentimeter nodules, and SBRT otherwise.
Currently, there is too limited evidence for the value of ablative techniques in curative treatment of
early stage NSCLC. Therefore, these therapies should only be used in expert centers for selected
patients in clinical studies.
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Lung cancer is a major health problem with no improvement in
survival over the last decades. Lung cancer is the leading cause of
cancer-related deaths worldwide, with 1.6 million lung cancer
deaths each year [1]. After the age of 45 years, the incidence of
lung cancer greatly increases in both males and females. Despite
improvements in surgical treatment, chemotherapy and radio-
therapy, the long-term survival of lung cancer remains low [2].
The lack of improvement in long-term survival is mostly
due to the fact that lung cancer is still generally diagnosed at
a late stage: more than two-thirds of the patients present with
regional or distance metastases [3]. However, more recently
the introduction of personalized medicine with targeted ther-
apy and immunotherapy with PD1 – PD-L1 inhibitors may
improve outcome for advanced disease. Most patients with
early-stage lung cancer are asymptomatic that leads to delays
in diagnosis. Lung cancer survival is strongly related to stage
at time of diagnosis, with 5 year survival decreasing from 85%
for treated stage IA disease, to around 6% for stage IV disease
[4]. However, in routine clinical care, only 15% of lung cancer
cases are stage I at diagnosis, and curability of lung cancer
diagnosed at later stages greatly decreases [5,6].
1.1. Low-dose CT lung cancer screening
Low-dose computed tomography (CT) imaging was first intro-
duced in the 1990s [7]. Advances in multi-detector CT
scanners have made high-resolution imaging in a single
breath hold possible with radiation exposure less than 20%
of the exposure from diagnostic chest CT scanning [8].
Recently, the largest lung cancer screening trial worldwide,
the National Lung Screening Trial (NLST) concluded that
annual screening by low-dose CT reduces lung cancer specific
mortality by 20%, compared to screening by chest X-ray. Other
trials compared CT-screening with no screening [9–13]. Most
of these trials are ongoing.
The promising results of the NLST have led to a positive
recommendation on lung cancer screening by the United
States Preventive Services Task Force at the end of 2013, and
to the announcement of the US Centers for Medicare and
Medicare services on the immediate cover of lung cancer
screening with low dose computed tomography (LDCT) once
per year in a high risk population [14,15]. Currently, lung
cancer screening in the United States is rapidly expanding.
Although none of the European trials have shown benefit of
lung cancer screening by LDCT yet, also in Europe implemen-
tation of lung cancer screening is being discussed [16].
However, before lung cancer screening might be implemen-
ted in routine clinical care in Europe, some concerns should be
clarified. First, the results of the largest European randomized
controlled lung cancer screening trial, the Dutch–Belgian lung
cancer screening trial (Dutch acronym: NELSON), or if neces-
sary, the results of pooling of European trials with comparable
screen parameters and nodule management [17], should indi-
cate whether the results of the NLST are reproducible in
CONTACT Marjolein A Heuvelmans m.a.heuvelmans@umcg.nl Center for Medical Imaging - North East Netherlands, University Medical Center Groningen,
Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017
VOL. 11, NO. 2, 89–100
http://dx.doi.org/10.1080/17476348.2017.1276445
© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
another population. Second, the false-positive rate of up to
one out of four screenees as shown by the NLST should be
reduced. A screening and nodule management strategy
should be balanced, in terms of a high sensitivity for lung
cancer diagnosis and minimization of potential harms like
unnecessary additional CT examination and invasive workup
for benign nodules. Third, in the NSLT about 23% of patients
were diagnosed as stage IIIB/IV in incidence rounds for whom
screening is not valuable [18]. In the NELSON study, the rate of
stage IIIB/IV cancers increased from 7% after an annual screen,
to 17% after a 2.5 year screen interval [19]. It might be that not
all screenees should undergo regular screen CTs with equal
screen intervals, but that certain subgroups can be identified
based on prescreen lung cancer probability derived from
modeling [20,21], or based on previous screen results in
which the screen interval can be longer than 1 year to thereby
decrease radiation dose and costs [22,23]. Nevertheless, a
screen interval of 2.5 years seems to be too long [19].
1.2. Lung cancer screening studies and outcome
A number of single-arm cohort studies have been performed,
showing that lung cancer can be detected in an early stage by
screening by low-dose chest CT [24–28], The two largest low-
dose CT randomized controlled lung cancer screening trials
worldwide are the NLST and the NELSON trial. In the NLST,
53,454 current or former heavy smokers aged 55–74 years were
randomized to receive three annual low-dose chest CT screen-
ings or three annual screenings by chest X-ray. They found that
over a 7 year period, fewer participants died from lung cancer in
the CT screen group compared to the control group screened by
chest X-ray (17.6 per 1000 versus 20.7 per 1000, respectively). In
the CT-screen group, 649/26,722 (2.4%) of the participants was
diagnosed with lung cancer, and the majority of lung cancers
were detected in stage I (60.6%, Table 1).
The NELSON trial was launched in September 2003. Primary
object of this ongoing trial is to investigate whether chest CT
screening in year 1, 2, 4 and 6.5 will decrease lung cancer
mortality by at least 25% in high-risk (ex-) smokers between 50
and 75 years of age compared to a control group receiving no
screening. The NELSON trial is the first large lung cancer
screening trial in which nodule management is based on
semiautomatically determined nodule volume, instead of
manually measured nodule diameter, resulting in a lower
false-positive rate [9]. At incidence rounds, nodule growth of
previously detected nodules, in terms of volume-doubling
time (VDT), is decisive for the screen result. The final results,
expected in the upcoming years, will indicate whether a volu-
metry- and VDT based CT protocol is more efficient in terms of
detection rate, morbidity, mortality, recall rate, and cost-effec-
tiveness, compared to other approaches. Similar to the NLST, a
high percentage of 69% stage I cancers was detected in the
NELSON study (Table 1). Not only cancers from nodules
already detected at baseline were proven to be stage I in
the majority of cases, also more than two-third of malignant
nodules newly detected after baseline, and therefore relatively
fast-growing, were found to be stage I at time of diagno-
sis [34].
Additionally, a number of smaller randomized controlled
low-dose CT lung cancer screening trials were performed in
Europe [17]. Three of these studies already published their
final results. None of these studies showed a significant lung
cancer mortality benefit for the CT screen group [29,32,35],
possibly due to the limited sample sizes and unfavorable
randomization to the CT screen group [29]. The percentage
stage I cancers of the smaller trials, 45% to 72%, was far higher
than the percentage stage I cancers detected outside a screen-
ing program (Table 1).
Non-small cell lung cancer (NSCLC) accounts for over 85%
of lung cancer cases. Due to different screening approaches, in
terms of screen interval, number of screening rounds and
follow-up after screening, the exact lung cancer detection
rate and percentage of lung cancer stage per screenings
study should be compared with caution. However, Table 1
shows that the percentage of lung cancers (NSCLC and
SCLC) detected in early stage (stage I or stage II, according
to the seventh TNM classification [36]) is much higher in lung
cancer screening patients, compared to routine clinical care.
Results of the different randomized controlled lung cancer
screening trials showing only a limited number of stage II
cancers detected in screening (4–19%, mean 7.6%, Table 1
and Figure 1) suggest that stage II represents a relatively
short period in the development in lung cancer. In other
words, a lung cancer develops fast from a stage I cancer
with relatively good 5 years survival results when treated,
into a stage III cancer with far more limited survival.
1.3. Shift in treatment options for early stage lung
cancers
Up to 70% of screen-detected NSCLCs published by the dif-
ferent lung cancer screening trials were detected in stage IA
Table 1. Lung cancer stages and histology of different randomized-controlled lung cancer screening studies.
NLST [8] NELSON [19] DLCST [29] MILD [30] LUSI [31] ITALUNG [12] DANTE [32] UKLS [33]
Number of rounds 3 4 5 5 or 10 5 4 5 1
Screen interval (years) 1 1, 2, and 2.5 1 1 or 2 (randomized) 1 1 1 NA
Lung cancer detection rate (%) 649/26,722 (2.4) 255/7915 (3.2) 100/2052 (4.9) 50/2303 (2.5) 58/2028 (2.9) 35/1613
(2.2)
104/1264 (8.2) 42/1991 (2.1)*
Stage I cancers (%) 400/649 (60.6) 176/255 (69.0) 50/100 (50.0) 28/50 (56.0) 42/58 (72.4) 23/35 (65.7) 47/104 (45.2) 28/42 (66.7)
Stage II cancers (%) 46/649 (7.1) 21/255 (8.2) 4/100 (4.0) 4/50 (8.0) 6/58 (10.3) * 7/104 (6.7) 8/42 (19.0)
Stage III cancers (%) 108/649 (16.6) 42/255 (16.5) 23/100 (23.0) 6/50 (12.0) 7/58 (12.1) * 17/104 (16.3) 3/42 (7.1)
Stage IV cancers (%) 81/649 (12.5) 16/255 (6.3) 23/100 (23.0) 9/50 (18.0) 3/58 (5.2) * 26/104 (25.0) 3/42 (7.1)
*Not published separately; number of cancers stage II–IV: 12/35 (34.3%).
DLST: Danish Lung Cancer Screening Trial; ITALUNG: Italian Lung Study; LUSI: German Lung Cancer Screening Intervention Trial; MILD: Multicentric Italian Lung
Detection; NELSON: Nederlands Leuvens Longkanker Screenings Onderzoek (Dutch–Belgian Lung Cancer Screening Trial); NSLT: National Lung Screening Trial.
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(up to 3 cm diameter) or IB (>3–5 cm diameter; Table 1,
Figure 1), compared to up to 15% stage I NSCLCs in routine
clinical care [5,6]. The percentage screen-detected stage I
cancers may be lower as a result of a different screen protocol,
nodule management protocol, or selection of screen partici-
pants. The higher rate of early stage cancers indicates that,
after implementation of lung cancer screening in routine clin-
ical care, a shift in lung cancer treatment options will take
place, from mainly management for advanced stage to treat-
ment options with curative intent for early stage cancers.
Currently, anatomic surgical resection with systematic lymph
node evaluation is recommended as standard treatment for
operable patients with early stage NSCLC according to the
National Comprehensive Cancer Network (NCCN) guidelines
[34]. For medically inoperable patients stereotactic body
radiation therapy (SBRT) is currently the recommended treat-
ment. Interest in alternative investigative nonsurgical treat-
ment options such as radiofrequency ablation (RFA),
microwave ablation (MWA), percutaneous cryotherapy (PCT)
photodynamic therapy (PDT) and heavy particle irradiation is
increasing, although these techniques are still experimental
and are used in the setting of clinical studies. Up to now, no
randomized trials were finished comparing the different treat-
ment options. This article will review the pros and cons and
clinical evidence so far for both surgical and nonsurgical treat-
ment options for clinical stage I NSCLC.
1.4. Should all patients with screen-detected stage i
cancers be treated?
If patients with stage I NSCLC are left untreated, median survival
is less than a year [37–39]. However, it is very important to
differentiate stage I NSLCL presenting as solid or partial-solid
nodules from those presenting as pure ground glass opacity
[40]. The latter group, mostly representing adenocarcinoma in
situ or minimally invasive adenocarcinoma, distinguish them-
selves from other stage I NSCLCs in terms of their nonaggres-
sive behavior. In a sub analysis on nonsolid nodules detected in
two studies on lung cancer screening, it was shown that despite
the relatively high risk of malignancy in these nodules, progres-
sion to cancer stage beyond stage I was extremely rare [41,42].
Yankelevitz et al. reported a lung cancer survival rate for
patients with a malignant nonsolid nodule of 100% after a
median follow-up period of 78 months since diagnosis, regard-
less the size of the nonsolid nodule [41]. Thus immediate
resection of pure ground glass nodules mostly should be dis-
couraged, and close follow-up of nonsolid nodules (SSNs) by
annual LDCT usually is sufficient, to reduce overdiagnosis and
overtreatment of lung cancer screening participants.
1.5. Importance of histopathological diagnosis
In a substantial part of patients undergoing minimal invasive
treatment methods like SBRT for a suspicious solitary pulmon-
ary nodule, no definitive tissue diagnosis will be obtained.
Table 2. Stepwise approach for the treatment of (screen-detected) stage I
NSCLC.
1 Define nodule consistency.
Pure ground glass nodule: consider watchful waiting;
(Partial)-solid: proceed to step 2.
2 Test if patient is eligible for, and willing to undergo surgery:
Yes: proceed to step 3;
No: proceed to step 4.
3 Define nodule size
≤1 cm: Consider VATS sublobar resection
>1 cm: recommended treatment: (VATS) lobectomy. Alternative
for selected patients*: VATS sublobar resection, preferably
segmentectomy.
4 Specify stage and location:
Stage IA (≤3 cm), peripheral: proceed to step 5;
Stage IA (≤3 cm), central: proceed to step 6;
Stage IB (>3–5 cm) peripheral: proceed to step 7;
Stage IB (>3–5 cm) central: proceed to step 7.
5 Recommended treatment: SBRT. Investigational alternatives that
might be considered in a clinical study: RFA, MWA, PCT
6 Recommended treatment: SBRT. Investigational alternatives that
might be considered in a clinical study: (NSCLC <1 cm): PCT, PDT
7 Recommended treatment: SBRT.
VATS: video-assisted thoracoscopy; SBRT: stereotactic body radiation therapy;
RFA: radiofrequency ablation; MWA: microwave ablation; PCT: percutaneous
cryoablation; PDT, photodynamic therapy.
* Might be considered for elderly patients with peripheral stage I (adenocarci-
noma) ≤2 cm in size
Figure 1. Total overview cancer stage distribution of the randomized-controlled low-dose CT lung cancer screening trials, shown as percentage (dots) with standard
deviation (vertical bars). A total of 1,258 lung cancers in 46,075 screen participants were described by the different studies. ITALUNG data were excluded because of
missing stage distribution for cancers beyond stage I.
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Recently, models for estimation of lung cancer probability
were established, indicating that patients with positron emis-
sion tomography (PET)-positive new or growing solitary pul-
monary nodules with a >85% pretest probability of
malignancy are eligible for treatment with SBRT [43]. No dif-
ference in overall survival or local control in patients with or
without pathologically proven lung cancer was found in a
population with a low incidence of benign PET-positive lung
nodules [44].
The smaller the nodule, the less likely that histopathologi-
cal diagnosis can be obtained. In such cases nodule growth
will determine the probability of malignancy, as the majority
of very small lung cancers (<8 mm) will be FDG negative
[45,46]. These patients will be treated as if having stage I
NSCLC. Some centers will prefer a wait-and-see policy, some
use transthoracic needle biopsy before treatment to obtain
tissue for confirmation of malignancy, and some start with a
video assisted thoracoscopic wedge resection. Therefore, dif-
ferent algorithms have been advocated to estimate the risk for
malignancy.
Since a single positive lymph node will lead to an upsta-
ging from stage I to at least stage II NSCLC, pretreatment
mediastinal staging is important. Imaging tools such as a
diagnostic CT and PET are valuable in the evaluation of med-
iastinal lymph nodes, however false-negative (5–15%) and
false-positive (up to 53%) may not be neglected. Therefore,
nowadays lymph node staging is supplemented with endo-
bronchial ultrasound-guided (EBUS) or endoscopic ultrasound
transbronchial needle aspiration (EUS). In patients treated with
surgery, the American College of Chest Physicians (ACCP) and
other societies recommend systematic mediastinal lymph
node sampling at time of anatomic resection for accurate
pathologic staging [47].
2. Surgical treatment options along the line of
lobectomy, segmentectomy, wedge resections
Since the implementation of lobectomy, it has been the recom-
mended first-line treatment for patients with early-stage NSCLC
who are able to undergo surgery [48]. Nevertheless, it is impor-
tant that lung cancer surgery is performed in a center with high
procedure volume, to increase survival, in particular in the early
postoperative period [49]. One great benefit of surgical techni-
ques compared to nonsurgical techniques as discussed below, is
the possibility to gather a definitive tissue diagnosis and the
best local tumor control. Based on the lung cancer’s histologic
subtype and mediastinal lymph node staging, an accurate
pathological staging can be performed. Furthermore, the histo-
logic sample can be used to obtain information on lung cancer’s
DNA mutation status, which is especially valuable in case of
progressive disease.
2.1. Prior to surgery: eligibility of the patient
According to the U.S. Preventive Services Task Force, persons
eligible for lung cancer screening have smoked at least 30
pack-years. Since smoking is the most important risk factor not
only for lung cancer, but also for severe comorbidities like
chronic obstructive pulmonary disease (COPD). and coronary
heart disease, it is not surprising that up to 25% of patients
with screen detected lung cancer are not eligible for surgery
[50,51]. According to the ACCP step-by-step approach for the
preoperative evaluation of lung cancer patients, patients who
are candidates for surgical treatment should undergo both
spirometry (forced expiratory volume in 1 second [FEV1]) and
measurement of diffusing capacity for CO (DLCO) [52]. In
patients with FEV1 or DCLO <60% of predicted, the postopera-
tive predicted volume is estimated. In case of postoperative
predictive volume between 30% and 60%, the participant is
designated of being at increased operative risk. For those
patients, it is necessary to evaluate patient’s exercise capacity,
for instance by ergometry (Vo2 max estimation) or a 6 min
walk test (cutoff point eligible for surgery of 400 m). In case of
a calculated postoperative predictive FEV1 or DLCO of <30%,
this cardiopulmonary exercise test gives an indication of the
risk on perioperative morbidity and mortality [52]. Treatment
options for early stage NSCLC patients with comorbid condi-
tions precluding surgical resection are discussed below.
2.2. Lobectomy, open thoracotomy versus minimally
invasive techniques
Lobectomy via thoracotomy including mediastinal lymphade-
nectomy has been the standard-of-care for years. Five-year
overall survival rates for patients with stage I NSCLC treated
with lobectomy via open thoracotomy are in the range of 60%
to 80% [53,54]. Another approach is video-assisted thoraco-
scopic surgery (VATS) which is a minimally invasive alternative
to open thoracotomy. A randomized controlled trial compar-
ing open thoracotomy and VATS for the treatment of stage I
NSCLC in terms of survival has not been performed. However,
in a large study using data of the National Cancer Data Base,
retrospectively analyzing over 30,000 lobectomies performed
for stage I lung cancer between 2010 and 2012, was found
that about one-third of lobectomies were performed mini-
mally invasive via VATS or robot-assisted [55]. After compar-
ison with open lobectomy, they found that minimally invasive
lobectomy was associated with shorter length of hospital stay,
and was not associated with increased perioperative mortality
or reduced short-term survival when compared with the open
approach [55]. Another advantage of the VATS approach over
open thoracoscopy is the fact that it can be performed in
patients with worse preoperative pulmonary function tests
[56]. Nodal upstaging beyond stage I was found to occur
more commonly in open thoracoscopy compared with mini-
mally invasive lobectomy (12.8% versus 10.3%), but this differ-
ence was no longer statistically significantly different for
patients who were treated in an experienced clinic. This sug-
gests that minimally invasive lobectomies should be per-
formed only in high-volume centers with significant
experience [57]. Comparable results have been described by
other studies [58–61], indicating lobectomy via VATS as a
more favorable approach in the treatment of stage I NSCLC
compared to open thoracoscopy. Recently, a randomized con-
trolled trial was published comparing postoperative pain and
quality of life for patients with early lung cancer treated by
VATS lobectomy or open lobectomy. VATS lobectomy was
found to be associated with less postoperative pain and better
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quality of life compared to lobectomy by anterolateral thor-
acotomy for the first year after surgery [62]. Therefore, the
authors suggest that VATS should be the preferred surgical
approach for lobectomy in stage I NSCLC. The major question
is whether the hilar and mediastinal lymph nodes are ade-
quately explored when a VATS is performed. As indicated this
is mainly determined by experience of the surgeon.
More recently, robot-assisted thoracoscopic surgery has
been used in the treatment of stage I NSCLC. Compared to
open lobectomy, robot-assisted thoracoscopic surgery was
associated with shorter in-hospital stay and lower morbidity
and mortality, but significantly longer operating times [63,64]
. Only few small retrospective studies have been performed
comparing VATS and robot-assisted thoracoscopic surgery.
These studies suggest comparable perioperative outcomes
with fewer conversions for uncontrolled bleeding using the
robot-assisted thoracoscopic approach [65]. However, there
is a steep learning curve for robot-assisted thoracoscopic
surgery, and long-term randomized studies evaluating
robotic-assisted lobectomy and VATS lobectomy are still lack-
ing [66].
2.3. Sublobar resection versus lobectomy
Sublobar resection refers to either wedge-resection or seg-
mentectomy. Sublobar resection may be considered for
patients who cannot tolerate a lobectomy due to limited
pulmonary function, advanced age, or other extensive comor-
bidity. Comparing segmentectomy with wedge-resection,
Sienel et al. found a better cancer-related survival for patients
who underwent a segmentectomy [[67]. However, another
recent study suggests that for carefully staged cT1N0M0
NSCLC, segmentectomy and wedge-resection are associated
with comparable outcome in terms of survival [68]. Only lim-
ited data comparing sublobar resection with (VATS) lobectomy
is available. Dai et al. compared overall survival and lung
cancer-specific survival among 15,760 patients with stage IA
NSCLC after lobectomy, segmentectomy, or wedge resection
[69]. They found that lobectomy showed better survival than
sublobar resection. For NSCLC patients in whom lobectomy is
unsuitable, they recommended segmentectomy for tumors >1
to 2 cm because of better survival compared to wedge resec-
tion, whereas for tumors ≤1 cm survival was similar after
treatment with segmentectomy and wedge resection [69].
Tsutani et al. studied 610 patients with stage IA adenocarci-
noma who underwent surgical resection by either lobectomy
or segmentectomy, and looked into radiological characteristics
predicting survival. In a subgroup of 239 patients with ground-
glass-opacity-dominant (subsolid) primary tumors, no signifi-
cant difference in 3 year recurrence-free survival was observed
between patients who underwent lobectomy (96.4%), seg-
mentectomy (96.1%), and wedge resection (98.7%) [70].
Using data of the National Cancer Data Base, it was found
that patients with stage IA NSCLC treated with sublobar resec-
tion had significant worse overall survival compared with
lobectomy [71]. Median OS for lobectomy, segmentectomy,
and wedge resection were 100, 74, and 68 months, respec-
tively (p < .001). This retrospective study showed that surgical
margins were more often positive, fewer lymph nodes were
examined and significantly lower rates of nodal upstaging
were found in patients treated with sublobar resections [71].
Two multicenter, prospective, randomized studies com-
paring lobectomy versus sublobar resection for small (≤
2 cm) peripheral NSCLC are currently ongoing (Cancer and
Leukemia Group B 140503; Japanese Clinical Oncology
Group 0802/West Japan Oncology Group 4607L). Results of
these trials will help to define the selection criteria for
sublobar resection in the treatment of NSCLC patients. The
first prospective, multicenter, randomized controlled trial
comparing sublobar resection and lobectomy for elderly
patients with clinical stage T1N0M0 NSCLC has recently
been announced. Primary outcome of this trial is 3 years
disease-free survival. In total 339 subjects will be enrolled,
and participants will be followed-up every 6 months post-
operation for 3 years [72]. Until now, sublobar resections
may have equivalent outcomes to lobectomy in well-
selected patients with small (up to 2 cm) NSCLC, and in
whom an adequate resection margin can be achieved, for
instance those with small peripherally located tumors with
favorable histopathology, and with ground-glass opacity on
imaging [73–75].
2.4. After surgery: adjuvant chemotherapy or
postoperative radiotherapy
Adjuvant chemotherapy might be considered for patients with
a stage IB NSCLC with diameter of more than 4 cm. For
patients with resected stage IA tumors, adjuvant chemother-
apy is not indicated. Postoperative radiotherapy is only indi-
cated for patients with stage I NSCLC with positive surgical
margins.
2.5. Summary surgical treatment options
In summary, lobectomy, preferably via VATS, including med-
iastinal lymph node dissection is the recommended treatment
option for patients with stage I NSCLC with adequate lung
function and no major comorbid conditions precluding sur-
gery. Sublobar resection preferably segmentectomy via VATS
can be performed in well-selected patients with small (<2 cm)
peripheral ground-glass-opacity-dominant nodules or semiso-
lid nodules, and in whom an adequate resection margin can
be achieved.
3. Nonsurgical treatment options
About 25% of patients with screen detected lung cancer are
not eligible for surgery due to comorbid conditions, often
caused by smoking. A disadvantage of lobectomy for a small
subcentimeter nodule is the relative large loss of normal lobar
tissue. After a lobectomy loss in lung function is about 11%. If
for such patients VATS with wedge or segmentectomy is not
feasible, radiotherapy is an option.
SBRT has been shown to be an effective and safe alternative
for treatment of early stage lung cancer in medically inoperable
patients [76]. Furthermore, knowledge on other, investigational,
minimal invasive techniques like radiofrequency ablation, micro-
wave ablation, percutaneous cryotherapy and photodynamic
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therapy is increasing [76]. In particular SBRT has been advocated
to be equivalent to surgical resection in terms of local control
and survival outcomes in some cases.
3.1. Stereotactic body radiation therapy
SBRT, also known as stereotactic ablative radiotherapy (SABR)
uses precisely targeted radiation with very large doses per
fraction by using multiple convergent beams. The aim of the
technique is to destroy cancerous tissue, causing as little toxi-
city to adjacent normal tissue as reasonably possible. SBRT is
considered the standard treatment for stage I NSCLC patients
with comorbidities precluding surgical resection. Compared to
lobectomy or sublobar resection, it has a lower complication
rate with similar overall mortality [77]. Furthermore, in a rando-
mized controlled trial, the global health related quality of life
and indirect costs were found to be significantly favorable and
cheaper in patients treated with SBRT compared to patients
treated surgically [78].
A study on patients with severe COPD and early stage
NSCLC showed that patient treated with SBRT had significant
lower 30-days mortality compared to patients treated with
lobectomy, with comparable survival rates at one and
3 years despite negative selection of SBRT patients in terms
of comorbidities [79].
In a large retrospective study on SBRT in 676 patients with
early-stage NSCLC a 5 year local control of 89.5% was found.
After 5 years, any recurrence, most often isolated distant
recurrences that will probably not be affected by the local
treatment used, had occurred in 30% of patients. Median
overall survival was 40.7 months [80]. Other prospective
stage II studies on small, peripheral, biopsy-proven NSCLC
showed comparable 5 year local control rates of around
90% [81].
For elderly patients until at least age 85 years with stage I
NSCLC with multiple comorbid conditions precluding surgical
resections, treatment with SBRT (median overall survival
29 months) is found to be associated with improved survival
compared with observation alone (median survival 10 months;
p < .01) [82]. In addition, another study analyzing results of
251 patients stratified by age showed that elderly patients (at
least 75 years old) had similar rate of efficacy and risk of
toxicity as younger patients after SBRT treatment [83]. In this
particular group of elderly patients, a definitive treatment of
NSCLC sometimes is abandoned, due to limited estimated
survival time of the patient. However, results of Nanda et al.
and Mancini et al. suggest that SBRT should always be con-
sidered for elderly patients with an early stage lung cancer
[82,83].
3.1.1. Surgical resection versus SBRT in patients eligible for
surgery
After these positive results of the mostly smaller studies,
showing comparable survival after treatment with SBRT and
surgery, there has been increased interest in using SBRT as the
primary treatment for patients who are healthy enough for
surgery but prefer a less invasive treatment. Retrospective
comparisons of patients treated with SBRT or lobectomy
showed less favorable outcome for patients treated with
SBRT [84,85]. However, results of these comparisons were
possibly affected by patient selection bias, since patients trea-
ted with SBRT are more likely to be older and have more
comorbidities, making them less eligible for surgery. Rosen
et al. retrospectively compared survival data of patients with
stage I NSCLC that were healthy enough for surgery but
preferred SBRT over lobectomy [39]. In total, 13,652 patients
underwent lobectomy and 1781 patients medically fit for
operation underwent SBRT due to personal preferences.
Patients treated with SBRT were generally older and were
less likely to have adenocarcinoma. The first 7.5 months after
treatment, there were no differences in survival for the two
treatment options, but after 7.5 months survival lobectomy
was associated with a significantly better outcome than
stereotactic body radiotherapy [39].
Up to now, no large randomized controlled trials compar-
ing surgical resection with SBRT for early-stage NSCLC has
been finished due to poor accrual. Recently, pooled results
of two early-closed randomized controlled trials comparing
SBRT and lobectomy, the ROSEL and the STARS trial were
published. From the pooled results, including 58 patients
randomized to SBRT (31 patients) or surgery (27 patients), it
was concluded that SBRT could be a reasonable therapeutic
option for operable stage I lung cancer with better overall
survival (3 year overall survival of 95% for SBRT versus 79% for
lobectomy [76]. However, these results should be interpreted
carefully because of the limited sample size and short follow-
up: the possible ‘head-start effect’ for SBRT, where periopera-
tive mortality may obscure a later mortality benefit of surgery
[76]. Several retrospective studies have been performed com-
paring SBRT and surgical resection. Direct comparison of the
two treatment methods is challenged by the fact that most
patients treated with SBRT were older and had more comor-
bidities. Therefore, larger randomized controlled trials are
awaited to confirm the findings of Chang et al.
3.2. Lung ablation
In case patients with early-stage NSCLC, not eligible for both
SBRT and surgical resection, are able to undergo percutaneous
CT-guided needle biopsy, they might be candidates for image-
guided tumor ablation techniques like RFA, MWA or PCT.
These techniques are relatively new in the area of lung cancer
treatment, and were initially introduced for the percutaneous
treatment of hepatic malignancies. The goals of tumor abla-
tion are (1) ablation of the entire tumor and a margin of
normal parenchyma surrounding it, (2) to quickly create this
large ablation area, and (3) to avoid injury to critical structures
[86]. Up to now, there are no randomized controlled trials
comparing the different ablation techniques with each other,
with SBRT, or with surgical resection. Pending such studies,
ablative therapies for the treatment of NSCLC should only be
used for patients within clinical studies in expert centers.
3.2.1. Radiofrequency ablation
Among image-guided ablation as a treatment for stage I
NSCLC, RFA is the most common used technique, and the
major advantage of RFA over other ablation techniques is
experience. During RFA, an alternative current is generated
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by a radiofrequency generator, moving from an active elec-
trode inserted within the tumor, usually performed under CT
guidance, to dispersive electrodes placed on the patient. A
high-frequency electrical current is generated, causing heating
and coagulation of tumor tissue.
Important contraindications for treatment with RFA are
tumors surrounded by larger vessels and airways and centrally
located tumors. Due to the so-called heat-sink effect, the phe-
nomenon by which medium to large-sized blood vessels and
airways dissipate the thermal and electrical energy away from
adjacent tissue and target lesions [86], tumors near these struc-
tures may show less response than expected. Furthermore, RFA
is discouraged for central nodules and nodules located in the
lung apex or within 1 cm of major vessels, bronchus, nerves,
and esophagus, because of the risk of thermal injuries. A rela-
tive contraindication for RFA is tumor size; local control is
reduced in tumors with diameter >3 cm [87]. Complications of
RFA frequently occur, with a rate of major complications of
around 10% of lung ablations. The most common complica-
tions include pneumothorax, postprocedural pain, hemoptysis,
bronchopleural fistula, and rib fractures.
Most studies analyzing the efficacy of RFA in the treatment of
stage I NSCLC were performed retrospectively. These studies
concluded that RFA is a safe, feasible, and effective procedure
in medically inoperable clinical stage I NSCLC patients. In a
review of 14 studies regarding RFA for stage I NSCLC, 1-, 2-, 3-,
and 5 year overall survival rates were 78–100%, 53–86%, 36–88%,
and 25–61%, respectively [88]. The median survival time ranged
from 29 to 67 months. Recently, two prospective multicenter
studies published their results. Dupuy et al. studied RFA in 51
eligible patients. They found overall 1 and 2 year survival rates of
86.3% and 69.8%, respectively. For tumor size <2 cm, overall
2 year survival rate increased to 83% [89]. Gobara et al. enrolled
33 patients from eight institutions, however only seven patients
had stage I NSCLC [90]. For these seven patients, 1- and 2-year
overall survival rates comparable to Dupuy et al. were found
(83% and 63%, respectively).
3.2.2. Microwave ablation
MWA is perceived as a potentially superior treatment option
to RFA, due to enhanced tumor coagulation of tumor cells as a
result of improved energy deposition in the lung leading to
higher temperatures within the tumor in a shorter time period
and a larger ablation area. MWA uses electromagnetical waves
in the microwave energy spectrum that produce tissue-heat-
ing effects. By inducing kinetic energy within water molecules
surrounding the probe, these molecules start rotating rapidly,
and they transfer some of their kinetic energy to surrounding
tissue leading to tissue heating [86]. It is a novel technique in
the treatment of early stage lung cancer, with complications
comparable with RFA although MWA is associated with less
procedural pain. Compared with RFA, the heat-sink effect is
found to be smaller in MWA. However, in lesions close to large
vessels, treatment response can be less than expected.
Up to now, only few clinical studies on MWA, most of them
including both primary NSCLC and pulmonary metastases,
have been published. In a study by Wolf et al. of 50 patients
with 82 pulmonary masses (primary or pulmonary metastasis,
exact numbers not provided) treated with MW ablation, can-
cer-specific was 83%, 73%, and 61% at 1, 2, and 3 years post-
ablation, respectively [91]. After a mean follow-up of
10 months, 26% of patients had residual disease at the abla-
tion site, and 67% had local control at 1 year. Belfiore et al.
studied 69 unresectable lesions (44 NSCLC, 25 pulmonary
metastases) in 56 patients, and found comparable survival
rates [92]. One-year, 2 year and 3 year cancer-specific survival
was 69%, 54%, and 49%, respectively. The estimate mean
survival time was 27.8 months. None of the patients devel-
oped local recurrence during the study (mean follow-up time
not described). A study retrospectively analyzing 47 patients
with stage I medically inoperable NSCLC who were treated
with MWA found a median cancer-specific survival of
47.4 months [93]. Tumors ≤3.5 cm were associated with better
survival compared with lesions >3.5 cm. Pneumothorax was by
far the most common complication in the different studies,
with incidence of up to 64% [93], however chest tube insertion
was only necessitated in the minority of these cases and 30-
days mortality was very low.
3.2.3. Percutaneous cryoablation therapy
In contrary to the two heat-based ablation techniques, PCT
uses cold to destroy tissue. When a pressurized gas, usually
argon, reaches the end of the probe, located in the tumor
under CT-guidance, the gas expands and reaches ultralow
temperatures of as cold as −140 °C. An ice-ball is formed in
the tissue surrounding the probe, and cryogenic destruction
occurs directly as a result of protein denaturation and cell
rupture from ice crystals and osmotic shifts between intracel-
lular and extracellular water, and indirectly as result of hypoxic
tissue injury due to vasoconstriction, freezing of blood in small
vessels or occluded blood vessels [86,94]. PCT is performed
using an ablation scheme consisting of both freeze periods
and thaw periods, to reduce the chance of air leaks and
bleeding. One or more probes can be placed in a tumor
depending on its size, but lesions <3 cm are preferred.
The advantages of PCT over RFA include larger tumor
ablation volumes and less procedural pain due to the analge-
sic effect of freezing [94]. Since PCT is able to preserve col-
lagenous tissue and cellular architecture, in contrary to RFA,
this ablation technique is safer for patients with extensive
emphysema and for lesions near vascular structures or
bronchi. Furthermore, a highly visible ablation zone is created,
which allows for easy follow-up during the procedure.
Drawbacks of PCT compared to MWA and RFA include the
relatively long procedural time and the increased chance of
bleeding along the needle tract requiring intervention like
tract coagulation with fibrin glue.
Three studies focused on PCT for stage I NSCLC. Zemlyak
et al studied 27 patients [95]. After a mean follow-up of
33 months, they found a local control rate of 89%. 3 year
overall survival was 77%. Yamauchi et al. studied 22 patients
with 34 tumors who underwent 25 sessions of PCT for clinical
stage I NSCLC [96]. Median follow-up period was 23 months.
Local tumor progression after cryoablation was observed in
one squamous cell carcinoma (3%) of 1.6 cm in size. 3 year
overall survival was 88%. The third study retrospectively
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evaluated the 5 year survival in 45 patients with 47 primary
stage I NSCLC after PCT. 5 year overall survival was 68%. There
were no deaths associated with the cryoablation, however a
pneumothorax was seen in over 50% of cases and bleeding
occurred in two-fifth of cases, although most of which
minor [97].
3.2.4. Summary lung ablation
In summary, knowledge on ablative therapies in the treatment
of medically inoperable patients with stage IA NSCLC is
increasing. Most of the studies have been performed on larger
tumors. Ablation by cryo, microwave or radiofrequency proce-
dures may be reconsidered for small growing nodules with
novel positioning technologies.
A retrospective study compared the outcome of patients
with stage I NSCLC treated with either sublobar resection
(N = 25) or RFA (N = 12) or cryoablation (N = 27) in 64 patients
[95]. They found a comparable 3 year cancer-specific survival
for the three treatment options (90.6%, 87.5%, and 90.2%,
respectively. However, larger randomized-controlled trials
with longer follow-up comparing the different ablative treat-
ment options and comparing ablative therapies with SBRT and
lobectomy in the treatment of medically inoperable patients
with stage IA NSCLC need to be performed to confirm the first
results and to make recommendations for therapy. In these
comparison studies, patients of all treatment arms should
undergo comparable pre-treatment evaluation of the pre-
sence of mediastinal or distance metastases. Pending such
studies, ablative therapies for the treatment of NSCLC should
only be used in the scope of clinical studies in expert centers.
3.3. Other treatment options
Other novel investigative techniques for the treatment of
stage I NSCLC include heavy particle irradiation and photody-
namic therapy.
3.3.1. Heavy particle irradiation
In patients with stage I NSCLC, both proton beam and carbon
ion therapy have been used on an experimental basis.
Through the characteristic Bragg peak where protons and
carbon ions give the majority of their energy on the depth
where the radiation penetrates maximal in the tumor, the
dose to surrounding normal tissue is significantly reduced.
Preliminary results of a number of small studies investigating
proton beam and carbon ion therapy for stage I NSCLC sug-
gest that these approaches may yield results similar to con-
ventionally fractionated RT. Furthermore, a number of larger
clinical trials are underway [98]. For now, until more evidence
has been collected, heavy particle irradiation should not be
used in the treatment for stage I NSCLC outside the scope of
clinical trials.
3.3.2. Photodynamic therapy
Over the last several years, PDT has been used more fre-
quently in the treatment of thoracic malignancies. PDT uses
a photosensitizer combined with light to produce singlet oxy-
gen (1O2) that leads to damage of cancer cells through apop-
totic, necrotic, or autophagic tumor cell death. Simone et al.
reviewed available literature on the use of PDT for the treat-
ment of stage I NSCLC. They concluded from the different
studies with small sample sizes that PDT is most effective for
tumors with lengths ≤1 cm that have no extra cartilaginous
invasion and no radiologic findings on high-resolution CT
imaging, and that treatment by PDT might be an alternative
for surgery in medically inoperable tumors with a central stage
I NSCLC of <1 cm diameter [99]. More evidence on the effec-
tiveness of PCT for treatment of stage I NSCLC in larger clinical
studies should be collected to investigate the possible role of
this technique in the treatment of such cancers.
4. Summary
In conclusion, implementation of lung cancer screening, cur-
rently already in the United States and perhaps in the upcom-
ing years also in other parts of the world, will have major
therapeutic implications. Among screening participants, a
stage shift will occur from up to 15% stage I non-small cell
lung cancers (NSCLCs) in routine clinical practice to up to 70%
in lung cancer screening patients. This indicates that, after
implementation of lung cancer screening in routine clinical
care, a shift in lung cancer treatment options for advanced
stage to treatment options with curative intent for early stage
cancers may occur. Some of the pure ground-glass, nonag-
gressive, lung cancers will not require immediate treatment,
but close follow-up by CT-scans instead. For (partial) solid
stage I NSCLCs in medically operable patients, (VATS) lobect-
omy remains the standard of care, with sublobar resection as
an alternative treatment option in specific patient populations
such as subcentimeter solid nodules. For medically inoperable
patients, or in patients not willing to undergo surgery, SBRT is
the treatment of choice. In case of a patient with a stage IA
cancer presenting in a specialized clinic, more investigational
options like ablation may be considered only in scope of a
clinical study. More (prospective) studies on more investiga-
tive noninvasive treatment options like radiofrequency abla-
tion, microwave ablation, percutaneous cryotherapy and
photodynamic therapy, and randomized controlled trials com-
paring the different treatment options, in particular surgery
and SBRT, are awaited.
5. Expert commentary
Lung cancer screening by low-dose chest CT for high-risk
patients is already being implemented in routine clinical care
in the United States. From the different screening trials we
have learned that the large majority of screen-detected
NSCLCs is diagnosed in stage I (Table 1). For Europe, lung
cancer screening programs are not recommended yet, and
the final result of the largest European trial, the NELSON
trial, probably will be decisive in that discussion.
Nevertheless, the promising results of the NLST may not be
neglected. Furthermore, results of the different screening trials
showing only a limited number of stage II cancers detected in
screening (4% to 19%), suggest that stage II represents a
relatively short period in the development in lung cancer. In
other words, a lung cancer develops fast from a stage I cancer
with relatively good 5 years survival when treated, into a stage
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III cancer with far more limited survival, indicating the value of
screening programs.
Recommended treatment for stage I NSCLC remains (VATS)
lobectomy in case of a medically operable patient, VATS sub-
lobar resection for subcentimeter nodules, and SBRT other-
wise. Although novel techniques seem promising, there is too
limited evidence for the value of radiofrequency ablation,
microwave ablation, cryoablation, and photodynamic therapy
in curative treatment of early stage NSCLC. Therefore, these
therapies should only be used in expert centers for selected
patients in clinical studies (see Table 2).
6. Five-year view
With implementation of lung cancer screening, and further
optimization of imaging techniques, more and more small
pulmonary nodules inside and outside of lung cancer
screening programs will be detected. Patients with screen-
detected lung cancer are much more likely to present with
stage I lung cancer than are patients with lung cancer
diagnosed after medical symptoms. Thus, it might be
expected that discussion on the different treatment options
for early-stage lung cancer will increase. The selection cri-
teria for different surgical approaches will be evaluated in
clinical trials and sublobar resections in selected medically
operable patients will become implemented. However, in
particular for lung cancer screening patients with a stage I
pure ground-glass lung cancer, watchful waiting should be
considered because of the nonaggressive behavior of these
specific cancers. For medically inoperable patients, SBRT is
the standard of care. Although experience on ablation tech-
niques like RFA, MWA and PCT for treatment of early stage
lung cancers is increasing, prospective, preferably rando-
mized controlled trials in small tumors, should be performed
to gain more insight in the value of these techniques com-
pared to the current standard care. In these studies, patients
of all treatment arms should undergo comparable pretreat-
ment evaluation of the presence of mediastinal or distance
metastases to ensure stage I disease. These patients should
be eligible for all treatment arms to avoid selection bias. It
might be expected that in the upcoming years newer tech-
niques such as heavy particle irradiation and PDT will be
further elaborated in clinical studies.
Key issues
● In routine clinical practice, only about 15% of lung cancers
are still stage I at time of diagnosis.
● In high-risk patients screened by low-dose chest CT, up to
70% is diagnosed with stage I lung cancer.
● Implementation of lung cancer screening will lead to a shift
in treatment options for lung cancer in advanced stage to
treatment options in early staged cancers.
● Current guidelines recommend lobectomy as a first choice
for operable patients with early stage lung cancers.
● Sublobar resection refers to wedge resection or segmen-
tectomy. Since local recurrence rate is higher in patients
undergoing wedge resection, segmentectomy is recom-
mended as an alternative for lobectomy in selected patients
unable to undergo lobectomy, for instance elderly patients
with peripheral stage I adenocarcinoma presenting as a
ground-glass-opacity-dominant nodule ≤2 cm in size.
● VATS sublobar resection is preferred for subcentimeter
nodules.
● For medically inoperable patients with stage I NSCLC,
stereotactic body radiation therapy is the recommended
first choice treatment.
● Randomized controlled trials comparing stereotactic body
radiation therapy and lobectomy for operable patients have
been closed early due to poor accrual. Results of a pooled
analysis suggested that SBRT could be a reasonable ther-
apeutic option for operable stage I lung cancer with better
overall survival. However, more evidence from randomized
controlled is necessitated.
● Currently, there is only limited evidence for the value of
radiofrequency ablation, microwave ablation, cryoablation,
and photodynamic therapy in curative treatment of early
stage NSCLC. Therefore, these therapies should only be
used in expert centers for selected patients within clinical
studies.
Funding
This article was not funded.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert
testimony, grants or patents received or pending, or royalties.
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1 World Health Organisation. Cancer: fact Sheet no. 297. 2015. 2015
July 8. http://www.who.int/mediacentre/factsheets/fs297/en/.
2 Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010.. CA Cancer J
Clin. 2010;60(5):277–300.
3 Van Klaveren RJ. Lung cancer screening. Eur J Cancer. 2011;47
(Suppl 3):S147–55.
4 Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer
staging project: proposals for revision of the TNM stage groupings
in the forthcoming (eighth) edition of the tnm classification for
lung cancer. J Thorac Oncol. 2016;11(1):39–51.
5 Birim O, Kappetein AP, Takkenberg JJ, et al. Survival after patholo-
gical stage IA nonsmall cell lung cancer: tumor size matters. Ann
Thorac Surg. 2005;79(4):1137–1141.
6 Chansky K, Sculier JP, Crowley JJ, et al. The international association
for the study of lung cancer staging project: prognostic factors and
pathologic TNM stage in surgically managed non-small cell lung
cancer. J Thorac Oncol. 2009;4(7):792–801.
7 Naidich DP, Marshall CH, Gribbin C, et al. Low-dose CT of the lungs:
preliminary observations. Radiology. 1990;175(3):729–731.
8 National Lung Screening Trial Research Team, Aberle DR, Adams
AMBerg CD, et al. Reduced lung-cancer mortality with low-dose
computed tomographic screening. N Engl J Med. 2011; 365(5):395–
409.
•• A 20% reduction in lung cancer specific mortality was shown
in participants who were screened by an annual low-dose
EXPERT REVIEW OF RESPIRATORY MEDICINE 97
chest CT compared to participants who were screened by chest
radiography for three subsequent years.
9 Van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung
nodules detected by volume CT scanning. N Engl J Med. 2009;361
(23):2221–2229.
10 Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized
lung cancer CT screening trial–overall design and results of the
prevalence round. J Thorac Oncol. 2009;4(5):608–614.
11 Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with
spiral CT: baseline results of the randomized DANTE trial. Lung
Cancer. 2008;59(3):355–363.
12 Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment
and baseline results of the ITALUNG trial for lung cancer screening
with low-dose CT. Lung Cancer. 2009;64(1):34–40.
13 Becker N, Motsch E, Gross ML, et al. Randomized study on early
detection of lung cancer with MSCT in Germany: study design and
results of the first screening round. J Cancer Res Clin Oncol.
2012;138(9):1475–1486.
14. Humphrey LL, Deffebach M, Pappas M, et al. Screening for Lung
Cancer: Systematic Review to Update the U.S. Preventive Services
Task Force Recommendation. Ann Intern Med. 2013;159(6):411-420.
15 Centers for Medicare and Medicaid Services. Press release: national
coverage determination (NCD) for lung cancer screening with low
dose computed tomography (LDCT). 2015 June 28. https://www.
cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2015-
Press-releases-items/2015-02-05.html.
16 Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung
cancer screening. Eur Respir J. 2015;46(1):28–39.
17 Heuvelmans MA, Vliegenthart R, Oudkerk M. Contributions of the
european trials (european randomized screening group) in com-
puted tomography lung cancer screening. J Thorac Imaging.
2015;30(2):101-107.
18 Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence
screenings in the national lung screening trial. N Engl J Med.
2013;369(10):920–931.
19 Yousaf-Khan U, Van Der Aalst C, De Jong PA, et al. Final screening
round of the NELSON lung cancer screening trial: the effect of a
2.5-year screening interval. Thorax. 2017;72(1):48-56.
20 Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for
lung-cancer screening. N Engl J Med. 2013;368(8):728–736.
21 Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk
prediction to select smokers for screening CT–a model based on
the Italian COSMOS trial. Cancer Prev Res (Phila). 2011;4(11):1778–
1789.
22. Patz EF Jr, Greco E, Gatsonis C, et al. Lung cancer incidence and
mortality in national lung screening trial participants who under-
went low-dose CT prevalence screening: a retrospective cohort
analysis of a randomised, multicentre, diagnostic screening trial.
Lancet Oncol. 2016;17(5):590–599.
23 Heuvelmans MA, Oudkerk M. Determination of the optimal screen
interval in low-dose CT lung cancer screening: are we there yet?.
Transl Cancer Res. 2016;5(6):S1070–S1072.
24 Veronesi G, Maisonneuve P, Rampinelli C, et al. Computed tomo-
graphy screening for lung cancer: results of ten years of annual
screening and validation of cosmos prediction model. Lung Cancer.
2013;82(3):426–430.
25 International Early Lung Cancer Action Program Investigators,
Henschke CI, Yankelevitz DF, et al. Survival of patients with stage
I lung cancer detected on CT screening. N Engl J Med. 2006;355
(17):1763–1771.
26 Menezes RJ, Roberts HC, Paul NS, et al. Lung cancer screening
using low-dose computed tomography in at-risk individuals: the
Toronto experience. Lung Cancer. 2010;67(2):177–183.
27 Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung
Screening Study (PLuSS): outcomes within 3 years of a first com-
puted tomography scan. Am J Respir Crit Care Med. 2008;178
(9):956–961.
28 Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer:
five-year prospective experience. Radiology. 2005;235(1):259–265.
29 Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized
danish lung cancer screening trial with focus on high-risk profiling.
Am J Respir Crit Care Med. 2016;193(5):542–551.
30 Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomo-
graphy for lung cancer screening: comparison of performance
between annual and biennial screen. Eur Radiol. 2016;26
(11):3821-3829.
31 Becker N, Motsch E, Gross ML, et al. Randomized study on early
detection of lung cancer with msct in germany: results of the first 3
years of follow-up after randomization. J Thorac Oncol. 2015;10
(6):890–896.
32 Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results
of the dante trial, a randomized study of lung cancer screening
with spiral computed tomography. Am J Respir Crit Care Med.
2015;191(10):1166–1175.
33 Field JK, Duffy SW, Baldwin DR, et al. UK Lung cancer rct pilot
screening trial: baseline findings from the screening arm provide
evidence for the potential implementation of lung cancer screen-
ing. Thorax. 2016;71(2):161–170.
34 Walter JE, Heuvelmans MA, De Jong PA, et al. Occurrence and lung
cancer probability of new solid nodules at incidence screening with
low-dose CT: analysis of data from the randomised, controlled
NELSON trial. Lancet Oncol. 2016;17(7):907-916.
• A considerable higher lung cancer risk was shown in partici-
pants with a new nodule detected during incidence lung can-
cer screening. This finding may be directly translated into
routine clinical practice when a patient with an incidental
nodule at CT had a CT in the previous 2 years not showing
the nodule. These nodules should be followed more closely
than prevalent nodules to be detected in stage I.
35 Mario S, Nicola S, Carmelinda M, et al. Long-term surveillance of
ground-glass nodules: evidence from the MILD trial. J Thorac
Oncol. 2012;7(10):1541–1546.
36 Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer
staging project: proposals for the revision of the TNM stage group-
ings in the forthcoming (seventh) edition of the TNM classification
of malignant tumours. J Thorac Oncol. 2007;2(8):706–714.
37 Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung
cancer over time. J Thorac Oncol. 2008;3(7):781–792.
38 Wao H, Mhaskar R, Kumar A, et al. Survival of patients with non-
small cell lung cancer without treatment: a systematic review and
meta-analysis. Syst Rev. 2013;2:10-4053-2-10.
39 Rosen JE, Salazar MC, Wang Z, et al. Lobectomy versus stereotactic
body radiotherapy in healthy patients with stage I lung cancer. J
Thorac Cardiovasc Surg. 2016;152(1):44–54.e9.
40 Heuvelmans MA, Oudkerk M. Management of subsolid pulmonary
nodules in CT lung cancer screening. J Thorac Dis. 2015;7(7):1103–
1106.
41 Yankelevitz DF, Yip R, Smith JP, et al. CT screening for lung cancer:
nonsolid nodules in baseline and annual repeat rounds. Radiology.
2015;277(2):555-564.
42 Scholten ET, De Jong PA, De Hoop B, et al. Towards a close
computed tomography monitoring approach for screen detected
subsolid pulmonary nodules?. Eur Respir J. 2015;45(3):765–773.
43 Louie AV, Senan S, Patel P, et al. When is a biopsy-proven diagnosis
necessary before stereotactic ablative radiotherapy for lung can-
cer?: A decision analysis. Chest. 2014;146(4):1021–1028.
44 Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereo-
tactic ablative radiotherapy following a clinical diagnosis of stage I
NSCLC: comparison with a contemporaneous cohort with pathologi-
cally proven disease. Radiother Oncol. 2011;101(2):250–254.
45 Veronesi G, Bellomi M, Veronesi U, et al. Role of positron emission
tomography scanning in the management of lung nodules
detected at baseline computed tomography screening. Ann
Thorac Surg. 2007;84(3):959-65;discussion 965-6.
98 M. A. HEUVELMANS ET AL.
46 Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emis-
sion tomography and volume doubling time in lung cancer screen-
ing with low-dose CT scanning. Thorax. 2011;66(4):315–319.
47 Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II
non-small cell lung cancer: diagnosis and management of lung can-
cer, 3rd ed: American college of chest physicians evidence-based
clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S.
48 American College of Chest Physicians, Scott WJ, Howington J,
Feigenberg S, et al. Treatment of non-small cell lung cancer stage
I and stage II: ACCP evidence-based clinical practice guidelines
(2nd edition). Chest. 2007;132(3 Suppl):234S–242S.
49 Luchtenborg M, Riaz SP, Coupland VH, et al. High procedure
volume is strongly associated with improved survival after lung
cancer surgery. J Clin Oncol. 2013;31(25):3141–3146.
50 Donington J, Ferguson M, Mazzone P, et al. American college of
chest physicians and society of thoracic surgeons consensus state-
ment for evaluation and management for high-risk patients with
stage I non-small cell lung cancer. Chest. 2012;142(6):1620–1635.
51 Van Der Drift MA, Karim-Kos HE, Siesling S, et al. Progress in
standard of care therapy and modest survival benefits in the treat-
ment of non-small cell lung cancer patients in the Netherlands in
the last 20 years. J Thorac Oncol. 2012;7(2):291–298.
52 Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the
patient with lung cancer being considered for resectional surgery:
diagnosis and management of lung cancer, 3rd ed: American
college of chest physicians evidence-based clinical practice guide-
lines. Chest. 2013;143(5 Suppl):e166S–90S.
53 Little AG, Gay EG, Gaspar LE, et al. National survey of non-small cell
lung cancer in the United States: epidemiology, pathology and
patterns of care. Lung Cancer. 2007;57(3):253–260.
54 Ma L, Xiang J. Clinical outcomes of video-assisted thoracic surgery
and stereotactic body radiation therapy for early-stage non-small
cell lung cancer: A meta-analysis. Thorac Cancer. 2016;7(4):442–
451.
55 Yang CF, Sun Z, Speicher PJ, et al. Use and outcomes of minimally
invasive lobectomy for stage i non-small cell lung cancer in the
national cancer data base. Ann Thorac Surg. 2016;101(3):1037–
1042.
56 Burt BM, Kosinski AS, Shrager JB, et al. Thoracoscopic lobectomy is
associated with acceptable morbidity and mortality in patients
with predicted postoperative forced expiratory volume in 1 second
or diffusing capacity for carbon monoxide less than 40% of normal.
J Thorac Cardiovasc Surg. 2014;148(1):19-28, dicussion 28-29.e1.
57 Medbery RL, Gillespie TW, Liu Y, et al. Nodal upstaging is more
common with thoracotomy than with vats during lobectomy for
early-stage lung cancer: an analysis from the national cancer data
base. J Thorac Oncol. 2016;11(2):222–233.
58 Swanson SJ, Herndon JE, D’Amico TA, et al. Video-assisted thoracic
surgery lobectomy: report of CALGB 39802–a prospective, multi-
institution feasibility study. J Clin Oncol. 2007;25(31):4993–4997.
59 Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thor-
acoscopic lobectomy is less costly and morbid than open lobect-
omy: a retrospective multiinstitutional database analysis. Ann
Thorac Surg. 2012;93(4):1027–1032.
60 Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoraco-
scopic surgery versus open lobectomy for primary non-small-cell
lung cancer: a propensity-matched analysis of outcome from the
European Society of Thoracic Surgeon database. Eur J Cardiothorac
Surg. 2016;49(2):602–609.
61 Nwogu CE, D’Cunha J, Pang H, et al. VATS lobectomy has better
perioperative outcomes than open lobectomy: CALGB 31001, an
ancillary analysis of CALGB 140202 (Alliance). Ann Thorac Surg.
2015;99(2):399–405.
62 Bendixen M, Jorgensen OD, Kronborg C, et al. Postoperative pain
and quality of life after lobectomy via video-assisted thoracoscopic
surgery or anterolateral thoracotomy for early stage lung cancer: a
randomised controlled trial. Lancet Oncol. 2016;17(6):836–844.
• A randomized controlled trial comparing lobectomy via VATS
and open lobectomy, showing less postoperative pain and a
better quality of life after lobectomy via VATS. The effectiveness
of the two techniques has not been described in this paper.
[63] Veronesi G, Galetta D, Maisonneuve P, et al. Four-arm robotic
lobectomy for the treatment of early-stage lung cancer. J Thorac
Cardiovasc Surg. 2010;140(1):19–25.
64 Cerfolio RJ, Bryant AS, Skylizard L, et al. Initial consecutive experi-
ence of completely portal robotic pulmonary resection with 4 arms.
J Thorac Cardiovasc Surg. 2011;142(4):740–746.
65 Mahieu J, Rinieri P, Bubenheim M, et al. Robot-assisted thoraco-
scopic surgery versus video-assisted thoracoscopic surgery for lung
lobectomy: can a robotic approach improve short-term outcomes
and operative safety?. Thorac Cardiovasc Surg. 2016;64(4):354–362.
66 Brooks P. Robotic-assisted thoracic surgery for early-stage lung
cancer: A review. Aorn J. 2015;102(1):40–49.
67 Sienel W, Dango S, Kirschbaum A, et al. Sublobar resections in
stage IA non-small cell lung cancer: segmentectomies result in
significantly better cancer-related survival than wedge resections.
Eur J Cardiothorac Surg. 2008;33(4):728–734.
68 Altorki NK, Kamel MK, Narula N, et al. Anatomical segmentectomy
and wedge resections are associated with comparable outcomes
for small cT1N0 non-small cell lung cancer. J Thorac Oncol. 2016;11
(11):1984-1992.
69 Dai C, Shen J, Ren Y, et al. Choice of surgical procedure for patients
with nsclc 1 to 2 cm among lobectomy, segmentectomy, and
wedge resection: a population-based study. J Clin Oncol. 2016;34
(26):3175-3182.
70 Tsutani Y, Miyata Y, Nakayama H, et al. Appropriate sublobar
resection choice for ground glass opacity-dominant clinical stage
IA lung adenocarcinoma: wedge resection or segmentectomy.
Chest. 2014;145(1):66–71.
71 Khullar OV, Liu Y, Gillespie T, et al. Survival after sublobar resection
versus lobectomy for clinical stage ia lung cancer: an analysis from
the national cancer data base. J Thorac Oncol. 2015;10(11):1625–
1633.
72 Yang F, Sui X, Chen X, et al. Sublobar resection versus lobectomy in
surgical treatment of elderly patients with early-stage non-small
cell lung cancer (STEPS): study protocol for a randomized con-
trolled trial. Trials. 2016;17:191.
73 Cao C, Gupta S, Chandrakumar D, et al. Meta-analysis of intentional
sublobar resections versus lobectomy for early stage non-small cell
lung cancer. Ann Cardiothorac Surg. 2014;3(2):134–141.
74 Cao C, Chandrakumar D, Gupta S, et al. Could less be more?-A
systematic review and meta-analysis of sublobar resections versus
lobectomy for non-small cell lung cancer according to patient
selection. Lung Cancer. 2015;89(2):121–132.
75 Sesti J, Donington JS. Sublobar Resection: ongoing controversy for
treatment for stage i non-small cell lung cancer. Thorac Surg Clin.
2016;26(3):251–259.
76 Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiother-
apy versus lobectomy for operable stage I non-small-cell lung
cancer: a pooled analysis of two randomised trials. Lancet Oncol.
2015;16(6):630–637.
•• Pooling of randomized trials directly comparing stereotactic
ablative radiotherapy and lobectomy for operable stage I
NSCLC, showing that SABR could be an option for treating
operable stage I NSCLC. However, this study only had a small
patient sample size and short follow-up, so additional rando-
mised studies comparing SABR with surgery in operable
patients are warranted.
77 Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5
treatment strategies for early-stage non-small cell lung cancer in
the elderly. Int J Radiat Oncol Biol Phys. 2012;84(5):1060–1070.
78 Louie AV, Van Werkhoven E, Chen H, et al. Patient reported out-
comes following stereotactic ablative radiotherapy or surgery for
stage IA non-small-cell lung cancer: results from the ROSEL multi-
center randomized trial. Radiother Oncol. 2015;117(1):44–48.
79 Palma DA, Senan S. Early-stage non-small cell lung cancer in elderly
patients: should stereotactic radiation therapy be the standard of
care?. Int J Radiat Oncol Biol Phys. 2012;84(5):1058–1059.
EXPERT REVIEW OF RESPIRATORY MEDICINE 99
80 Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease
recurrence after stereotactic ablative radiotherapy for early stage
non-small-cell lung cancer: a retrospective analysis. Lancet Oncol.
2012;13(8):802–809.
81 Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation
therapy for inoperable early stage lung cancer. Jama. 2010;303
(11):1070–1076.
82 Nanda RH, Liu Y, Gillespie TW, et al. Stereotactic body radiation
therapy versus no treatment for early stage non-small cell lung
cancer in medically inoperable elderly patients: a National Cancer
Data Base analysis. Cancer. 2015;121(23):4222–4230.
83 Mancini BR, Park HS, Harder EM, et al. Elderly patients undergoing
SBRT for inoperable early-stage NSCLC achieve similar outcomes to
younger patients. Lung Cancer. 2016;97:22–27.
84 Puri V, Crabtree TD, Bell JM, et al. Treatment outcomes in stage i
lung cancer: a comparison of surgery and stereotactic body radia-
tion therapy. J Thorac Oncol. 2015;10(12):1776–1784.
85 Eba J, Nakamura K, Mizusawa J, et al. Stereotactic body radiother-
apy versus lobectomy for operable clinical stage IA lung adenocar-
cinoma: comparison of survival outcomes in two clinical trials with
propensity score analysis (JCOG1313-A). Jpn J Clin Oncol. 2016;46
(8):748-753.
86 Xiong L, Dupuy DE. Lung ablation: whats new?. J Thorac Imaging.
2016;31(4):228–237.
• Anupdate on ablative techniques for the treatment of lung cancer.
87 Sharma A, Abtin F, Shepard JA. Image-guided ablative therapies for
lung cancer. Radiol Clin North Am. 2012;50(5):975–999.
88 Hiraki T, Gobara H, Iguchi T, et al. Radiofrequency ablation for early-
stage nonsmall cell lung cancer. Biomed Res Int. 2014;152087:2014.
89 Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of
stage IA non-small cell lung cancer in medically inoperable patients:
results from the American College of Surgeons Oncology Group
Z4033 (Alliance) trial. Cancer. 2015;121(19):3491–3498.
90 Gobara H, Arai Y, Kobayashi T, et al. Percutaneous radiofrequency
ablation for patients with malignant lung tumors: a phase II pro-
spective multicenter study (JIVROSG-0702). Jpn J Radiol. 2016;34
(8):556-563.
91 Wolf FJ, Grand DJ, Machan JT, et al. Microwave ablation of lung
malignancies: effectiveness, CT findings, and safety in 50 patients.
Radiology. 2008;247(3):871–879.
92 Belfiore G, Ronza F, Belfiore MP, et al. Patients’ survival in lung
malignancies treated by microwave ablation: our experience on 56
patients. Eur J Radiol. 2013;82(1):177–181.
93 Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of
stage I medically inoperable non-small cell lung cancer: clinical
evaluation of 47 cases. J Surg Oncol. 2014;110(6):758–763.
94 Wang H, Littrup PJ, Duan Y, et al. Thoracic masses treated with
percutaneous cryotherapy: initial experience with more than 200
procedures. Radiology. 2005;235(1):289–298.
95 Zemlyak A, Moore WH, Bilfinger TV. Comparison of survival after
sublobar resections and ablative therapies for stage I non-small cell
lung cancer. J Am Coll Surg. 2010;211(1):68–72.
96 Yamauchi Y, Izumi Y, Hashimoto K, et al. Percutaneous cryoablation
for the treatment of medically inoperable stage I non-small cell
lung cancer. Plos One. 2012;7(3):e33223.
97 Moore W, Talati R, Bhattacharji P, et al. Five-year survival after
cryoablation of stage I non-small cell lung cancer in medically
inoperable patients. J Vasc Interv Radiol. 2015;26(3):
312–319.
98 Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus state-
ment on proton therapy in early-stage and locally advanced
non-small cell lung cancer. Int J Radiat Oncol Biol Phys.
2016;95(1):505–516.
99 Simone CB, Cengel KA. Photodynamic therapy for lung cancer and
malignant pleural mesothelioma. Semin Oncol. 2014;41(6):820–
830.
100 M. A. HEUVELMANS ET AL.
